Triple negative breast cancer (TNBC) accounts for 5–25% of all breast cancers, and is classified as tumors that are clinically negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 [HER2; (2, 3)]. This evidence concerns the gene ESR1 and breast cancer.